Evidence map›Paper›PMID 34654450›Full record

ArticleJournal of neuroinflammation2021

Inhibition of vascular adhesion protein 1 protects dopamine neurons from the effects of acute inflammation and restores habit learning in the striatum.

Serena Becchi, Alberto Buson, Bernard W Balleine

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Corticosterone accelerates behavioral inflexibility via plasticity-related gene expression in the dorsal striatum.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  2. Article
  3. The role of VAP-1 in cardiovascular disease: a review.Frontiers in cardiovascular medicine · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Serena BecchiDecision Neuroscience Lab, School of Psychology, UNSW Sydney, Randwick, NSW, 2052, Australia.
Alberto BusonAegros Pharmaceuticals, Sydney, Australia.
Bernard W BalleineDecision Neuroscience Lab, School of Psychology, UNSW Sydney, Randwick, NSW, 2052, Australia. bernard.balleine@unsw.edu.au.ORCID http://orcid.org/0000-0001-8618-7950
UNSW Sydney · AU

Funding

australian research council DP160105070australian research council DP200103401national health and medical research council GNT1175420
6 · The paper itself

Abstract

backgroundChanges in dopaminergic neural function can be induced by an acute inflammatory state that, by altering the integrity of the neurovasculature, induces neuronal stress, cell death and causes functional deficits. Effectively blocking these effects of inflammation could, therefore, reduce both neuronal and functional decline. To test this hypothesis, we inhibited vascular adhesion protein 1 (VAP-1), a membrane-bound protein expressed on the endothelial cell surface, that mediates leukocyte extravasation and induces oxidative stress.

methodWe induced dopaminergic neuronal loss by infusing lipopolysaccharide (LPS) directly into the substantia nigra (SN) in rats and administered the VAP-1 inhibitor, PXS-4681A, daily.

resultsLPS produced: an acute inflammatory response, the loss of dopaminergic neurons in the SN, reduced the dopaminergic projection to SN target regions, particularly the dorsolateral striatum (DLS), and a deficit in habit learning, a key function of the DLS. In an attempt to protect SN neurons from this inflammatory response we found that VAP-1 inhibition not only reduced neutrophil infiltration in the SN and striatum, but also reduced the associated striatal microglia and astrocyte response. We found VAP-1 inhibition protected dopamine neurons in the SN, their projections to the striatum and promoted the functional recovery of habit learning. Thus, we reversed the loss of habitual actions, a function usually dependent on dopamine release in DLS and sensitive to striatal dysfunction.

conclusionsWe establish, therefore, that VAP-1 inhibition has an anti-inflammatory profile that may be beneficial in the treatment of dopamine neuron dysfunction caused by an acute inflammatory state in the brain.

Indexed as

HabitsAllyl CompoundsAmine Oxidase (Copper-Containing)AnimalsAnti-Inflammatory Agents, Non-SteroidalBenzenesulfonamidesCell Adhesion MoleculesCorpus StriatumDopaminergic NeuronsInflammationLearningMaleRatsRats, WistarSulfonamides4-(2-(aminomethyl)-3-fluoroallyloxy)benzenesulfonamideAllyl CompoundsAmine Oxidase (Copper-Containing)Anti-Inflammatory Agents, Non-SteroidalBenzenesulfonamidesCell Adhesion MoleculesSulfonamidesvascular adhesion protein-1, ratBlood–brain barrierDopamine neuronsDorsolateral striatumHabit learningInflammationVAP-1

Identifiers

PMID34654450
PMCPMC8520223
OpenAlexW3179771077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.